Cannabics Pharmaceuticals Inc. (CNBX) 0.2700 $CNBX
Post# of 273330
Posted On: 04/12/2015 11:02:07 AM
Cannabics Pharmaceuticals Inc. (CNBX) 0.2700 $CNBX
Cannabics Pharmaceuticals Inc. Engages with the Technion Institute for the Screening of Potential Anticancer Cannabinoid Compounds
PR Newswire - Mon Apr 06, 7:30AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) announced today that it has executed a Research Agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential Anticancer Cannabinoid compounds.
Cannabics Pharmaceuticals Inc. Engages with the Technion Institute for Screening of Potential Anticancer Cannabinoid Compounds
ACCESSWIRE - Thu Apr 02, 6:25PM CDT
BETHESDA, MD / ACCESSWIRE / April 2, 2015 / Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) announced today that it has executed a Research Agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential Anticancer Cannabinoid compounds.
Anorexia Nervosa Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tzf2t/anorexia_nervosa) has announced the addition of the "Anorexia Nervosa Global Clinical Trials Review, H1, 2015" report to their offering. Anorexia Nervosa Global Clinical Trials Review, H1, 2015 provides data on the Anorexia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anorexia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anorexia Nervosa. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Anorexia Nervosa Therapeutics Clinical Trials - Sky Growth Acquisition Corporation - Medionics International Inc - Daiichi Sankyo Company, Limited - Cannabics Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - BioGaia AB - AstraZeneca PLC - Arjun Healthcare - Anaborex, Inc. For more information visit http://www.researchandmarkets.com/research/7t...ia_nervosa
AZN: 69.91 (-0.25), BMY: 64.64 (+1.18)
48 Marijuana Stocks - A Post-Mortem: Part II
Anthony Cataldo - at Seeking Alpha - Wed Mar 04, 7:36AM CST
INSY: 57.97 (+0.06), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27)
117 Marijuana Stocks For Your Do Not 'Buy-And-Hold' List
Anthony Cataldo - at Seeking Alpha - Fri Feb 06, 10:14AM CST
GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27)
99 Marijuana Stocks For Your Do Not 'Buy And Hold' List
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 6:25AM CST
GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27), ICN: 21.42 (-0.02)
Marijuana Firms - Exploring N=99, Ranked By Market Capitalization
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 3:34AM CST
GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27)
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part VIII
Anthony Cataldo - at Seeking Alpha - Wed Jan 28, 6:48AM CST
GWPH: 91.32 (+0.38), DE: 89.07 (+0.62), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27)
Cannabics Pharmaceuticals engages with Mountain High Products in Colorado
PR Newswire - Thu Dec 18, 8:41AM CST
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has executed a letter of engagement with Mountain High Products in Colorado, for the manufacturing and distribution of Cannabics SR medical cannabis products in the Colorado market.
American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks
Anthony Cataldo - at Seeking Alpha - Sun Dec 07, 5:36PM CST
GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03)
Cannabics Pharmaceuticals Signs IP Licensing and Collaboration Agreement in Spain
Marketwired - Thu Nov 06, 7:32AM CST
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has executed an IP Licensing and Collaboration Agreement with Kalapa Holding (Spain) for the production and distribution of CANNABICS SR medical cannabis products in the Spanish market.
Cannabics Pharmaceuticals, Inc. to Present at Cannabis Investor Webcast
ACCESSWIRE - Mon Oct 27, 7:01PM CDT
Bethesda, MD / ACCESSWIRE / October 27, 2014 / Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) will be presenting at the Cannabis Investor Webcast on Tuesday, October 28, 2014 at 11:00 AM ET.
Cannabics Pharmaceuticals Receives Cannabinoid R&D Lab Certification in Israel
Marketwired - Mon Oct 20, 8:05AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has received Government Certification from the Ministry of Health in Israel for the establishment of an advanced R&D laboratory dedicated to medical research in the field of cannabinoid science.
Cannabics Pharmaceuticals, Inc. (CNBX) Attains GMP Compliance, Prepares for First Clinical Study of Cannabics SR
Marketwire - Fri Sep 26, 7:30AM CDT
Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX), a developer of advanced medical cannabis therapies, announces that it has achieved Good Manufacturing Practices (GMP) capabilities as the Company moves toward the launch of its first clinical study of Cannabics SR capsules.
Cannabics Pharmaceuticals recruits two former senior Teva Executives to its Advisory Board
Business Wire - Tue Aug 19, 2:23PM CDT
Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) announced today that the Company has made two key appointments to the Company's Advisory Board with the recent recruitment of Mr. Ika Abravanel as senior advisor in the field of operational and strategic planning, and Dr. Sigalit Ariely-Portnoy, as senior advisor in the field of regulation, validation and quality.
Cannabics Pharmaceuticals Inc. Engages with the Technion Institute for the Screening of Potential Anticancer Cannabinoid Compounds
PR Newswire - Mon Apr 06, 7:30AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) announced today that it has executed a Research Agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential Anticancer Cannabinoid compounds.
Cannabics Pharmaceuticals Inc. Engages with the Technion Institute for Screening of Potential Anticancer Cannabinoid Compounds
ACCESSWIRE - Thu Apr 02, 6:25PM CDT
BETHESDA, MD / ACCESSWIRE / April 2, 2015 / Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) announced today that it has executed a Research Agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential Anticancer Cannabinoid compounds.
Anorexia Nervosa Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tzf2t/anorexia_nervosa) has announced the addition of the "Anorexia Nervosa Global Clinical Trials Review, H1, 2015" report to their offering. Anorexia Nervosa Global Clinical Trials Review, H1, 2015 provides data on the Anorexia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anorexia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anorexia Nervosa. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Anorexia Nervosa Therapeutics Clinical Trials - Sky Growth Acquisition Corporation - Medionics International Inc - Daiichi Sankyo Company, Limited - Cannabics Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - BioGaia AB - AstraZeneca PLC - Arjun Healthcare - Anaborex, Inc. For more information visit http://www.researchandmarkets.com/research/7t...ia_nervosa
AZN: 69.91 (-0.25), BMY: 64.64 (+1.18)
48 Marijuana Stocks - A Post-Mortem: Part II
Anthony Cataldo - at Seeking Alpha - Wed Mar 04, 7:36AM CST
INSY: 57.97 (+0.06), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27)
117 Marijuana Stocks For Your Do Not 'Buy-And-Hold' List
Anthony Cataldo - at Seeking Alpha - Fri Feb 06, 10:14AM CST
GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27)
99 Marijuana Stocks For Your Do Not 'Buy And Hold' List
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 6:25AM CST
GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27), ICN: 21.42 (-0.02)
Marijuana Firms - Exploring N=99, Ranked By Market Capitalization
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 3:34AM CST
GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27)
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part VIII
Anthony Cataldo - at Seeking Alpha - Wed Jan 28, 6:48AM CST
GWPH: 91.32 (+0.38), DE: 89.07 (+0.62), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27)
Cannabics Pharmaceuticals engages with Mountain High Products in Colorado
PR Newswire - Thu Dec 18, 8:41AM CST
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has executed a letter of engagement with Mountain High Products in Colorado, for the manufacturing and distribution of Cannabics SR medical cannabis products in the Colorado market.
American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks
Anthony Cataldo - at Seeking Alpha - Sun Dec 07, 5:36PM CST
GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03)
Cannabics Pharmaceuticals Signs IP Licensing and Collaboration Agreement in Spain
Marketwired - Thu Nov 06, 7:32AM CST
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has executed an IP Licensing and Collaboration Agreement with Kalapa Holding (Spain) for the production and distribution of CANNABICS SR medical cannabis products in the Spanish market.
Cannabics Pharmaceuticals, Inc. to Present at Cannabis Investor Webcast
ACCESSWIRE - Mon Oct 27, 7:01PM CDT
Bethesda, MD / ACCESSWIRE / October 27, 2014 / Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) will be presenting at the Cannabis Investor Webcast on Tuesday, October 28, 2014 at 11:00 AM ET.
Cannabics Pharmaceuticals Receives Cannabinoid R&D Lab Certification in Israel
Marketwired - Mon Oct 20, 8:05AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has received Government Certification from the Ministry of Health in Israel for the establishment of an advanced R&D laboratory dedicated to medical research in the field of cannabinoid science.
Cannabics Pharmaceuticals, Inc. (CNBX) Attains GMP Compliance, Prepares for First Clinical Study of Cannabics SR
Marketwire - Fri Sep 26, 7:30AM CDT
Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX), a developer of advanced medical cannabis therapies, announces that it has achieved Good Manufacturing Practices (GMP) capabilities as the Company moves toward the launch of its first clinical study of Cannabics SR capsules.
Cannabics Pharmaceuticals recruits two former senior Teva Executives to its Advisory Board
Business Wire - Tue Aug 19, 2:23PM CDT
Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) announced today that the Company has made two key appointments to the Company's Advisory Board with the recent recruitment of Mr. Ika Abravanel as senior advisor in the field of operational and strategic planning, and Dr. Sigalit Ariely-Portnoy, as senior advisor in the field of regulation, validation and quality.
(0)
(0)